Our results could explain how Burosumab positively affects on skeletal muscle of XLH patients reducing FGF23 action, since we have reported that FGF23 is able to impair myogenic differentiation reducing the expression of MRFs. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.